TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis.

Transl Neurodegener

The Neuro's Early Drug Discovery Unit (EDDU), Department of Neurology and Neurosurgery, Montreal Neurological Institute-Hospital, McGill University, 3801 University Street, Montreal, QC, H3A 2B4, Canada.

Published: December 2022

Amyotrophic lateral sclerosis (ALS) is a disease characterized by upper and lower motor neuron (MN) loss with a signature feature of cytoplasmic aggregates containing TDP-43, which are detected in nearly all patients. Mutations in the gene that encodes TDP-43 (TARBDP) are known to result in both familial and sporadic ALS. In ALS, disruption of neuromuscular junctions (NMJs) constitutes a critical event in disease pathogenesis, leading to denervation atrophy, motor impairments and disability. Morphological defects and impaired synaptic transmission at NMJs have been reported in several TDP-43 animal models and in vitro, linking TDP-43 dysregulation to the loss of NMJ integrity in ALS. Through the lens of the dying-back and dying-forward hypotheses of ALS, this review discusses the roles of TDP-43 related to synaptic function, with a focus on the potential molecular mechanisms occurring within MNs, skeletal muscles and glial cells that may contribute to NMJ disruption in ALS.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9793560PMC
http://dx.doi.org/10.1186/s40035-022-00331-zDOI Listing

Publication Analysis

Top Keywords

tdp-43 dysregulation
8
amyotrophic lateral
8
lateral sclerosis
8
tdp-43
6
als
6
dysregulation neuromuscular
4
neuromuscular junction
4
junction disruption
4
disruption amyotrophic
4
sclerosis amyotrophic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!